Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis-Reference-Cited by-同舟云学术

Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis

Published:2016-04-21 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Wang Yongjun¹,Parker Claire E²,Bhanji Tania³,Feagan Brian G²⁴⁵,MacDonald John K²⁴

Affiliation:

1. University of Western Ontario; Schulich School of Medicine & Dentistry; London ON Canada

2. Robarts Clinical Trials; Cochrane IBD Group; 100 Dundas Street, Suite 200 London ON Canada N6A 5B6

3. University of Western Ontario; Internal Medicine; London ON Canada

4. University of Western Ontario; Department of Medicine; London ON Canada

5. University of Western Ontario; Department of Epidemiology and Biostatistics; London ON Canada

Publisher

Wiley

Subject

Pharmacology (medical)

Reference153 articles.

1. 5-aminosalicylic acid versus salazopirin (SASP) in the oral treatment of active ulcerative colitis (UC) and in remission;Andreoli;Clinical Controversies in Inflammatory Bowel Disease,1987

2. Therapeutic effectiveness and tolerance of 5-aminosalicylic acid in short term treatment of patients with ulcerative colitis at a low or medium phase of activity;Bresci;International Journal of Tissue Reactions,1990

3. Olsalazine versus sulfasalazine in the treatment of ulcerative colitis: randomized controlled clinical trial;Cai;Chinese Journal of Digestion,2001

4. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study;D'Haens;Alimentary Pharmacology and Therapeutics,2006

5. Treatment of ulcerative colitis with olsalazine and sulfasalazine: efficacy and side effects;Ewe;Scandinavian Journal of Gastroenterology,1988

Cited by 107 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MMX mesalamine in ulcerative colitis: Major advantages towards classical mesalamine formulations;Digestive and Liver Disease;2024-09

2. Readily Available Oral Prebiotic Protein Reactive Oxygen Species Nanoscavengers for Synergistic Therapy of Inflammation and Fibrosis in Inflammatory Bowel Disease;ACS Nano;2024-05-13

3. Personalized Treatment for Crohn’s Disease: Current Approaches and Future Directions;Clinical and Experimental Gastroenterology;2023-12

4. Optimización del tratamiento de la colitis ulcerosa leve a moderada: Consenso Delphi CU-Forum;Gastroenterología y Hepatología;2023-12

5. Integration of an Aptamer-Based Signal-On Probe and a Paper-Based Origami Preconcentrator for Small Molecule Biomarkers Detection;BioChip Journal;2023-09-21